Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
What has been your approach to percutaneous intervention for calcified nodules and threshold for intervention?
Related Questions
What type of DES should you opt for if a patient has or is concerned about possible nickel allergy?
What techniques do you use in the lab to reduce the amount of contrast that needs to be used in patients with CKD?
How do you decide between using a self-expanding supraannular valve and a balloon-expandable valve for TAVR in patients with severe aortic stenosis and a small aortic annulus?
Is there any difference between colchicine 0.5mg vs 0.6 mg for high risk coronary artery disease?
Would you consider an inpatient Mitraclip for patients with severe MR and severely reduced LVEF who have been turned down/high risk for surgery if there were ongoing challenges with afterload reduction and transitioning to intermittent dialysis due to recurrent flash pulmonary edema?
Do you recommend routine use of protamine for hemostasis at the end of a transfemoral TAVI?
How do you view the balance between opting for percutaneous coronary intervention and prioritizing optimal medical therapy as the initial treatment choice for patients with stable angina?
In patients with post-MI LV thrombus which resolves after 3-6 months of anticoagulation, would you consider surveillance imaging for thrombus recurrence if there is persistent apical akinesis?
What has been your experience with Coronary CTA with FFR results and its ability to accurately predict epicardial CAD on diagnostic LHC?
What factors influence your choice between low-dose DOAC therapy and dual antiplatelet therapy for the first 3 months after percutaneous left atrial appendage occlusion?
